BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 11, Issue 2
This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (4018)
All Articles published online
The chart showing PDF series, HTML series, Tables (1-5) series.
Item 
Count 
PDF451
HTML3453
Tables (1-5)101
 Sum=4005
Jan 14, 2005 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11(2): 255-259 [PMID: 15633226 DOI: 10.3748/wjg.v11.i2.255]
URL: https://www.wjgnet.com/1007-9327/full/v11/i2/255.htm
Number Citing Articles
1
Catriona Crossan, Emmanuel A Tsochatzis, Louise Longworth, Kurinchi Gurusamy, Brian Davidson, Manuel Rodríguez-Perálvarez, Konstantinos Mantzoukis, Julia O’Brien, Evangelos Thalassinos, Vassilios Papastergiou, Andrew Burroughs. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment 2015; 19(9): 1 doi: 10.3310/hta19090
2
Wilma Debernardi-Venon, Silvia Martini, Fiorella Biasi, Barbara Vizio, Angela Termine, Giuseppe Poli, Franco Brunello, Carlo Alessandria, Renato Bonardi, Giorgio Saracco, Mario Rizzetto, Alfredo Marzano. AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. Journal of Hepatology 2007; 46(6): 1026 doi: 10.1016/j.jhep.2007.01.017
3
Paul Angulo, Jason M. Hui, Giulio Marchesini, Ellisabetta Bugianesi, Jacob George, Geoffrey C. Farrell, Felicity Enders, Sushma Saksena, Alastair D. Burt, John P. Bida, Keith Lindor, Schuyler O. Sanderson, Marco Lenzi, Leon A. Adams, James Kench, Terry M. Therneau, Christopher P. Day. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45(4): 846 doi: 10.1002/hep.21496
4
Usama Bakry, Heba Ayeldeen, Ghada Ayeldeen, Olfat Shaker. Proceedings of SAI Intelligent Systems Conference (IntelliSys) 2016. Lecture Notes in Networks and Systems 2018; 15: 1085 doi: 10.1007/978-3-319-56994-9_75
5
H. Castel, P. Mathurin. Stéatohépatite non alcoolique. EMC - Endocrinologie - Nutrition 2011; 8(3): 1 doi: 10.1016/S1155-1941(11)50624-9
6
P. Tessari, A. Coracina, A. Cosma, A. Tiengo. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases 2009; 19(4): 291 doi: 10.1016/j.numecd.2008.12.015
7
Laurent Castera, Valérie Vilgrain, Paul Angulo. Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology & Hepatology 2013; 10(11): 666 doi: 10.1038/nrgastro.2013.175
8
Helen Lydatakis, Ieronymos Philippos Hager, Eyaggelia Kostadelou, Stavros Mpousmpoulas, Stavros Pappas, Ioannis Diamantis. Non‐invasive markers to predict the liver fibrosis in non‐alcoholic fatty liver disease. Liver International 2006; 26(7): 864 doi: 10.1111/j.1478-3231.2006.01312.x
9
Hind I. Fallatah. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014; 2014: 1 doi: 10.1155/2014/357287
10
Nahum Méndez‐Sánchez, Marco Arrese, Daniel Zamora‐Valdés, Misael Uribe. Treating nonalcoholic fatty liver disease. Liver International 2007; 27(9): 1157 doi: 10.1111/j.1478-3231.2007.01567.x
11
Jun Chen, Meng Yin, Kevin J. Glaser, Jayant A. Talwalkar, Richard L. Ehman. MR elastography of liver disease: State of the art. Applied Radiology 2013; : 5 doi: 10.37549/AR1982
12
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_32-1
13
Carmen Fierbinteanu Braticevici, Ioan Sporea, Eugenia Panaitescu, Laura Tribus. Value of Acoustic Radiation Force Impulse Imaging Elastography for Non-invasive Evaluation of Patients with Nonalcoholic Fatty Liver Disease. Ultrasound in Medicine & Biology 2013; 39(11): 1942 doi: 10.1016/j.ultrasmedbio.2013.04.019
14
Wenjing Sun, Hongli Cui, Ning Li, Yanling Wei, Shujie Lai, Yang Yang, Xinru Yin, Dong‐Feng Chen. Comparison of FIB‐4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non‐alcoholic fatty liver disease: A meta‐analysis study. Hepatology Research 2016; 46(9): 862 doi: 10.1111/hepr.12647
15
Georgiana-Emmanuela Gîlcă-Blanariu, Daniela Simona Budur, Dana Elena Mitrică, Elena Gologan, Oana Timofte, Gheorghe Gh Bălan, Vasile Andrei Olteanu, Gabriela Ștefănescu. Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease. Metabolites 2023; 13(11): 1115 doi: 10.3390/metabo13111115
16
Ayako Suzuki, James Lymp, Jenny St. Sauver, Paul Angulo, Keith Lindor. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver International 2006; 26(10): 1209 doi: 10.1111/j.1478-3231.2006.01362.x
17
Massimo Pinzani, Francesco Vizzutti, Umberto Arena, Fabio Marra. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5(2): 95 doi: 10.1038/ncpgasthep1025
18
Korakot Nganvongpanit, Akanit Itthiarbha, Siriwan Ong-Chai, Prachya Kongtawelert. Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia. Journal of Veterinary Science 2008; 9(3): 317 doi: 10.4142/jvs.2008.9.3.317
19
Navneet Kaur, Gitanjali Goyal, Ravinder Garg, Chaitanya Tapasvi, Sonia Chawla, Rajneet Kaur. Potential role of noninvasive biomarkers during liver fibrosis. World Journal of Hepatology 2021; 13(12): 1919-1935 doi: 10.4254/wjh.v13.i12.1919
20
Kengo Tomita, Toshiaki Teratani, Hirokazu Yokoyama, Takahiro Suzuki, Rie Irie, Hirotoshi Ebinuma, Hidetsugu Saito, Ryota Hokari, Soichiro Miura, Toshifumi Hibi. Serum Immunoglobulin A Concentration Is an Independent Predictor of Liver Fibrosis in Nonalcoholic Steatohepatitis Before the Cirrhotic Stage. Digestive Diseases and Sciences 2011; 56(12): 3648 doi: 10.1007/s10620-011-1771-2
21
Ferah Armutcu, Sumeyya Akyol, Fatma Ucar, Serpil Erdogan, Omer Akyol. . Advances in Clinical Chemistry 2013; 61: 67 doi: 10.1016/B978-0-12-407680-8.00004-X
22
Heitor Rosa, Edison Roberto Parise. Is there a place for serum laminin determination in patients with liver disease and cancer?. World Journal of Gastroenterology 2008; 14(23): 3628-3632 doi: 10.3748/wjg.14.3628
23
Luca Miele, Alessandra Forgione, Giovanni Gasbarrini, Antonio Grieco. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Translational Research 2007; 149(3): 114 doi: 10.1016/j.trsl.2006.11.011
24
Amy G. Shah, Alison Lydecker, Karen Murray, Brent N. Tetri, Melissa J. Contos, Arun J. Sanyal. Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2009; 7(10): 1104 doi: 10.1016/j.cgh.2009.05.033
25
Claudia Filozof, Barry J. Goldstein, Richard N. Williams, Arun Sanyal. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015; 75(12): 1373 doi: 10.1007/s40265-015-0437-3
26
Yoshito Itoh, Yuya Seko, Toshihide Shima, Tomoaki Nakajima, Kei Mizuno, Yusuke Kawamura, Norio Akuta, Kiyoaki Ito, Miwa Kawanaka, Akira Hiramatsu, Michiie Sakamoto, Kenichi Harada, Yoshihito Goto, Takeo Nakayama, Hiromitsu Kumada, Takeshi Okanoue. Accuracy of non‐invasive scoring systems for diagnosing non‐alcoholic steatohepatitis‐related fibrosis: Multicenter validation study. Hepatology Research 2018; 48(13): 1099 doi: 10.1111/hepr.13226
27
Fazilet Duygu, Suda Tekin Koruk, Hasan Karsen, Nurten Aksoy, Abdullah Taskin, Melek Hamidanoglu. Prolidase and Oxidative Stress in Chronic Hepatitis C. Journal of Clinical Laboratory Analysis 2012; 26(4): 232 doi: 10.1002/jcla.21510
28
Korakot Nganvongpanit, Burin Boonsri, Thatdanai Sripratak, Patsanan Markmee. Effects of one-time and two-time intra-articular injection of hyaluronic acid sodium salt after joint surgery in dogs. Journal of Veterinary Science 2013; 14(2): 215 doi: 10.4142/jvs.2013.14.2.215
29
Lucia Malaguarnera, Michelino D Rosa, Anna M Zambito, Nicola dell'Ombra, Roberto D Marco, Mariano Malaguarnera. Potential Role of Chitotriosidase Gene in Nonalcoholic Fatty Liver Disease Evolution. The American Journal of Gastroenterology 2006; 101(9): 2060 doi: 10.1111/j.1572-0241.2006.00680.x
30
Ki M. Mak, Rena Mei. Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease. The Anatomical Record 2017; 300(8): 1371 doi: 10.1002/ar.23567
31
Kaori Suzuki, Masato Yoneda, Kento Imajo, Hiroyuki Kirikoshi, Atsushi Nakajima, Shin Maeda, Satoru Saito. Transient elastography for monitoring the fibrosis of non‐alcoholic fatty liver disease for 4 years. Hepatology Research 2013; 43(9): 979 doi: 10.1111/hepr.12039
32
Masahiko Shimada, Hiromu Kawahara, Kazuaki Ozaki, Masayuki Fukura, Hirokazu Yano, Mutsumi Tsuchishima, Mikihiro Tsutsumi, Shujiro Takase. Usefulness of a Combined Evaluation of the Serum Adiponectin Level, HOMA-IR, and Serum Type IV Collagen 7S Level to Predict the Early Stage of Nonalcoholic Steatohepatitis. The American Journal of Gastroenterology 2007; 102(9): 1931 doi: 10.1111/j.1572-0241.2007.01322.x
33
Vlad Ratziu, Laurence Martin, Larysa Fedchuk, Thierry Poynard. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?. Biomarkers in Medicine 2009; 3(4): 353 doi: 10.2217/bmm.09.36
34
P. Angulo. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroentérologie Clinique et Biologique 2009; 33(10-11): 940 doi: 10.1016/j.gcb.2009.08.001
35
Haruka Nikai, Akira Sasaki, Akira Umemura, Naoto Takahashi, Hiroyuki Nitta, Risaburo Akasaka, Keisuke Kakisaka, Hidekatsu Kuroda, Kazuyuki Ishida, Yasuhiro Takikawa. Predictive scoring system for advanced liver fibrosis in Japanese patients with severe obesity. Surgery Today 2021; 51(9): 1513 doi: 10.1007/s00595-021-02266-w
36
Mangesh Pagadala, Claudia O. Zein, Arthur J. McCullough. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009; 13(4): 591 doi: 10.1016/j.cld.2009.07.011
37
Chun-Han Cheng, Chia-Ying Chu, Huan-Lin Chen, I-Tsung Lin, Chia-Hsien Wu, Yuan-Kai Lee, Ping-Jen Hu, Ming-Jong Bair. Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C. Journal of Microbiology, Immunology and Infection 2020; 53(4): 542 doi: 10.1016/j.jmii.2019.09.002
38
L. Castera. Quels outils pour le diagnostic non invasif de la stéatose et de la fibrose chez les patients atteints de stéatopathie métabolique ?. Gastroentérologie Clinique et Biologique 2009; 33(5): 405 doi: 10.1016/j.gcb.2009.02.030
39
Carolina Coimbra Marinho, Thales Bretas, Izabela Voieta, Leonardo Campos de Queiroz, Raiza Ruiz-Guevara, Antônio Lúcio Teixeira, Carlos Maurício Antunes, Aluízio Prata, José Roberto Lambertucci. Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for schistosomiasis mansoni: a field-based study in Brazil. Memórias do Instituto Oswaldo Cruz 2010; 105(4): 471 doi: 10.1590/S0074-02762010000400020
40
Jinghua Wang, Chengfu Xu, Yunhao Xun, Zhenya Lu, Junping Shi, Chaohui Yu, Youming Li. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Scientific Reports 2015; 5(1) doi: 10.1038/srep16494
41
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017; : 603 doi: 10.1007/978-94-007-7675-3_32
42
Rasha Tarif Hamza, Amel A. Elfaramawy, Nermine H. Mahmoud. Serum Pentraxin 3 Fragment as a Noninvasive Marker of Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. Hormone Research in Paediatrics 2016; 86(1): 11 doi: 10.1159/000446566
43
Vlad Ratziu, Julien Massard, Frederic Charlotte, Djamila Messous, Françoise Imbert-Bismut, Luninita Bonyhay, Mohamed Tahiri, Mona Munteanu, Dominique Thabut, Jean François Cadranel, Brigitte Le Bail, Victor de Ledinghen, Thierry Poynard. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6(1) doi: 10.1186/1471-230X-6-6
44
Masato Yoneda, Hironori Mawatari, Koji Fujita, Kyoko Yonemitsu, Shingo Kato, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Tomoyuki Iwasaki, Yasuo Terauchi, Shinji Togo, Shiro Maeyama, Atsushi Nakajima. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. Journal of Gastroenterology 2007; 42(5): 375 doi: 10.1007/s00535-007-2014-3
45
Mariana V. Machado, Helena Cortez-Pinto. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. Journal of Hepatology 2013; 58(5): 1007 doi: 10.1016/j.jhep.2012.11.021
46
Llorenç Caballería Rovira, Pere Torán Montserrat, María Antonia Auladell Llorens, Guillem Pera Blanco. Esteatosis hepática no alcohólica. Puesta al día. Atención Primaria 2008; 40(8): 419 doi: 10.1157/13125408
47
Takeshi Okanoue, Hayao Ebise, Toshihiro Kai, Masayuki Mizuno, Toshihide Shima, Junji Ichihara, Mikio Aoki. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. Journal of Gastroenterology 2018; 53(1): 129 doi: 10.1007/s00535-017-1355-9
48
Kun ZHOU, Lun Gen LU. Assessment of fibrosis in chronic liver diseases. Journal of Digestive Diseases 2009; 10(1): 7 doi: 10.1111/j.1751-2980.2008.00356.x
49
Hiroshi Ishiba, Yoshio Sumida, Yuya Seko, Saiyu Tanaka, Masato Yoneda, Hideyuki Hyogo, Masafumi Ono, Hideki Fujii, Yuichiro Eguchi, Yasuaki Suzuki, Masashi Yoneda, Hirokazu Takahashi, Takashi Nakahara, Kojiro Mori, Kazuyuki Kanemasa, Keiji Shimada, Kento Imajo, Kanji Yamaguchi, Takumi Kawaguchi, Atsushi Nakajima, Kazuaki Chayama, Toshihide Shima, Kazuma Fujimoto, Takeshi Okanoue, Yoshito Itoh. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. Hepatology Communications 2021; 5(4): 559 doi: 10.1002/hep4.1637
50
Dominique Roulot, Sébastien Czernichow, Hervé Le Clésiau, Jean-Luc Costes, Anne-Claire Vergnaud, Michel Beaugrand. Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. Journal of Hepatology 2008; 48(4): 606 doi: 10.1016/j.jhep.2007.11.020
51
Yasushi Honda, Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Nobuyoshi Kawamura, Asako Nogami, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Nobuyuki Horita, Satoru Saito, Takeshi Kaneko, Atsushi Nakajima. Meta‐analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease. Hepatology Research 2023; 53(3): 219 doi: 10.1111/hepr.13857
52
D. V. Garbuzenko. Principles of diagnosis and treatment of alcohol-induced liver fibrosis. Meditsinskiy sovet = Medical Council 2022; (7): 104 doi: 10.21518/2079-701X-2022-16-7-104-114
53
Masahiro Kikuchi, Kengo Tomita, Tadaki Nakahara, Naoto Kitamura, Toshiaki Teratani, Rie Irie, Hirokazu Yokoyama, Takahiro Suzuki, Terufumi Yokoyama, Takashi Taguchi, Shinobu Tanaka, Masaaki Noguchi, Tamiko Ohkura, Toshifumi Hibi. Utility of quantitative99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis. Scandinavian Journal of Gastroenterology 2009; 44(2): 229 doi: 10.1080/00365520802433249
54
H. Hesham A-Kader, Fayez K. Ghishan. Textbook of Clinical Pediatrics. 2012; : 2075 doi: 10.1007/978-3-642-02202-9_215
55
Giuseppe Derosa, Pamela Maffioli. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017; : 3 doi: 10.1007/978-94-007-7675-3_13
56
N.C. Chavez-Tapia, F. Sanchez-Avila, F. Vasquez-Fernandez, A. Torres-Machorro, F.I. Tellez-Avila, M. Uribe. Non-Alcoholic Fatty-Liver Disease in Pediatric Populations. Journal of Pediatric Endocrinology and Metabolism 2007; 20(10) doi: 10.1515/JPEM.2007.20.10.1059
57
Amila Suljić, Ines Konjević, Lamija Smaka, Saadet Leyla Suleymanoglu, Muamera Subašić, Nermina Sofić. CMBEBIH 2021. IFMBE Proceedings 2021; 84: 264 doi: 10.1007/978-3-030-73909-6_30
58
Ulrike W. Denzer, Stefan Lüth. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Practice & Research Clinical Gastroenterology 2009; 23(3): 453 doi: 10.1016/j.bpg.2009.03.002
59
Akiomi Yoshihisa, Yusuke Kimishima, Takatoyo Kiko, Yu Sato, Shunsuke Watanabe, Yuki Kanno, Satoshi Abe, Makiko Miyata-Tatsumi, Takamasa Sato, Satoshi Suzuki, Masayoshi Oikawa, Atsushi Kobayashi, Takayoshi Yamaki, Koichi Sugimoto, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki, Takafumi Ishida, Yasuchika Takeishi. Liver fibrosis marker, 7S domain of collagen type IV, in patients with pre-capillary pulmonary hypertension. International Journal of Cardiology 2018; 258: 269 doi: 10.1016/j.ijcard.2018.01.138
60
Kazuya Kitamori, Hisao Naito, Hazuki Tamada, Miya Kobayashi, Daisuke Miyazawa, Yuko Yasui, Kunihiro Sonoda, Satoru Tsuchikura, Naomi Yasui, Katsumi Ikeda, Takashi Moriya, Yukio Yamori, Tamie Nakajima. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. Environmental Health and Preventive Medicine 2012; 17(3): 173 doi: 10.1007/s12199-011-0235-9
61
Geoffrey C. Farrell, Claire Z. Larter. Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis. Hepatology 2006; 43(Supplement 1): S99 doi: 10.1002/hep.20973
62
Lokesh Basavarajappa, Jihye Baek, Shreya Reddy, Jane Song, Haowei Tai, Girdhari Rijal, Kevin J. Parker, Kenneth Hoyt. Multiparametric ultrasound imaging for the assessment of normal versus steatotic livers. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-82153-z
63
J. K. Dowman, J. W. Tomlinson, P. N. Newsome. Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2011; 33(5): 525 doi: 10.1111/j.1365-2036.2010.04556.x
64
L. Castera. Non-invasive diagnosis of steatosis and fibrosis. Diabetes & Metabolism 2008; 34(6): 674 doi: 10.1016/S1262-3636(08)74603-2
65
Hirayuki Enomoto, Yukihiro Bando, Hideji Nakamura, Shuhei Nishiguchi, Masafumi Koga. Liver fibrosis markers of nonalcoholic steatohepatitis. World Journal of Gastroenterology 2015; 21(24): 7427-7435 doi: 10.3748/wjg.v21.i24.7427
66
Eugenia Tsai, Tai-Ping Lee. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clinics in Liver Disease 2018; 22(1): 73 doi: 10.1016/j.cld.2017.08.004
67
David E. Amacher. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers 2014; 19(7): 541 doi: 10.3109/1354750X.2014.958535
68
Min Kim, Changhu Lee, Dae Yun Seo, Hyojung Lee, Jay D. Horton, Jiyoung Park, Philipp E. Scherer. The impact of endotrophin on the progression of chronic liver disease. Experimental & Molecular Medicine 2020; 52(10): 1766 doi: 10.1038/s12276-020-00520-8
69
Pierre M Gholam, Louis Flancbaum, Jason T Machan, Douglas A Charney, Donald P Kotler. Nonalcoholic Fatty Liver Disease in Severely Obese Subjects. The American Journal of Gastroenterology 2007; 102(2): 399 doi: 10.1111/j.1572-0241.2006.01041.x
70
Yoshio Sumida, Masato Yoneda, Hideyuki Hyogo, Kanji Yamaguchi, Masafumi Ono, Hideki Fujii, Yuichiro Eguchi, Yasuaki Suzuki, Shunsuke Imai, Kazuyuki Kanemasa, Koji Fujita, Kazuaki Chayama, Kohichiroh Yasui, Toshiji Saibara, Norifumi Kawada, Kazuma Fujimoto, Yutaka Kohgo, Takeshi Okanoue. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. Journal of Gastroenterology 2011; 46(2): 257 doi: 10.1007/s00535-010-0305-6
71
Giuseppe Derosa, Pamela Maffioli. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_13-1
72
J. Vergniol, V. de Ledinghen. Diagnostic non invasif de la fibrose hépatique : modalités pratiques d’utilisation des marqueurs sanguins et du FibroScan. Gastroentérologie Clinique et Biologique 2009; 33(4): 334 doi: 10.1016/j.gcb.2009.02.014
73
Mikako Obika, Hirofumi Noguchi. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research 2012; 2012: 1 doi: 10.1155/2012/145754
74
Iradj Maleki, Mahmood Reza Aminafshari, Tarang Taghvaei, Vahid Hosseini, Alireza Rafiei, Zhila Torabizadeh, Maryam Barzin, Elahe Orang. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World Journal of Gastroenterology 2014; 20(35): 12566-12573 doi: 10.3748/wjg.v20.i35.12566
75
Pratima Nangia-Makker, Victor Hogan, Vitaly Balan, Avraham Raz. Chimeric galectin-3 and collagens: Biomarkers and potential therapeutic targets in fibroproliferative diseases. Journal of Biological Chemistry 2022; 298(12): 102622 doi: 10.1016/j.jbc.2022.102622
76
M.A. Karsdal, S.H. Nielsen, D.J. Leeming, L.L. Langholm, M.J. Nielsen, T. Manon-Jensen, A. Siebuhr, N.S. Gudmann, S. Rønnow, J.M. Sand, S.J. Daniels, J.H. Mortensen, D. Schuppan. The good and the bad collagens of fibrosis – Their role in signaling and organ function. Advanced Drug Delivery Reviews 2017; 121: 43 doi: 10.1016/j.addr.2017.07.014
77
Giada Sebastiani, Alfredo Alberti. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World Journal of Gastroenterology 2006; 12(23): 3682-3694 doi: 10.3748/wjg.v12.i23.3682
78
Hideyuki KANEMOTO, Koichi OHNO, Manabu SAKAI, Ko NAKASHIMA, Masashi TAKAHASHI, Yasuhito FUJINO, Hajime TSUJIMOTO. Blood Hyaluronic Acid as a Marker for Canine Cirrhosis. Journal of Veterinary Medical Science 2009; 71(9): 1251 doi: 10.1292/jvms.71.1251
79
Takeshi Okanoue, Michiie Sakamoto, Kenichi Harada, Masaya Inagaki, Naoko Totsuka, Gaia Hashimoto, Hiromitsu Kumada. Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study. Hepatology Research 2021; 51(9): 943 doi: 10.1111/hepr.13695
80
Francesco Vizzutti;, Umberto Arena;, Valerio Nobili;, Roberto Tarquini;, Marco Trappoliere;, Giacomo Laffi;, Fabio Marra;, Massimo Pinzani. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology 2009; 8(2): 89 doi: 10.1016/S1665-2681(19)31784-3
81
Thierry Poynard, Vlad Ratziu, Frederic Charlotte, Djamila Messous, Mona Munteanu, Françoise Imbert-Bismut, Julien Massard, Luninita Bonyhay, Mohamed Tahiri, Dominique Thabut, Jean François Cadranel, Brigitte Le Bail, Victor de Ledinghen. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6(1) doi: 10.1186/1471-230X-6-34
82
Changhu Lee, Min Kim, Jun Ho Lee, Jiyoung Oh, Hyun‐Hee Shin, Sang Min Lee, Philipp E Scherer, Hyug Moo Kwon, Jang Hyun Choi, Jiyoung Park. COL6A3‐derived endotrophin links reciprocal interactions among hepatic cells in the pathology of chronic liver disease. The Journal of Pathology 2019; 247(1): 99 doi: 10.1002/path.5172
83
Umiko Ishizaki, Michinobu Nagao, Yumi Shiina, Kenji Fukushima, Tatsunori Takahashi, Yamato Shimomiya, Yuka Matsuo, Kei Inai, Shuji Sakai. Prediction of Fontan-Associated Liver Disease Using a Novel Cine Magnetic Resonance Imaging “Vortex Flow Map” in the Right Atrium. Circulation Journal 2018; 82(8): 2143 doi: 10.1253/circj.CJ-17-1260
84
Vincenza Calvaruso, Antonio Craxì. Implication of normal liver enzymes in liver disease. Journal of Viral Hepatitis 2009; 16(8): 529 doi: 10.1111/j.1365-2893.2009.01150.x
85
R. M. Williamson, J. F. Price, P. C. Hayes, S. Glancy, B. M. Frier, G. I. Johnston, R. M. Reynolds, M. W. J. Strachan. Prevalence and markers of advanced liver disease in type 2 diabetes. QJM 2012; 105(5): 425 doi: 10.1093/qjmed/hcr233
86
Masato Yoneda, Takashi Uchiyama, Shingo Kato, Hiroki Endo, Koji Fujita, Kyoko Yoneda, Hironori Mawatari, Hiroshi Iida, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Noritoshi Kobayashi, Kensuke Kubota, Satoru Saito, Shiro Maeyama, Mina Sagara, Hiroyuki Aburatani, Tatsuhiko Kodama, Atsushi Nakajima. Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH). BMC Gastroenterology 2008; 8(1) doi: 10.1186/1471-230X-8-53
87
George V. Papatheodoridis, Emilia Hadziyannis, Emmanuel Tsochatzis, Anastasia Georgiou, Georgia Kafiri, Dina G. Tiniakos, Katerina Margariti, Spilios Manolakopoulos, Emanuel K. Manesis, Athanasios J. Archimandritis. Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2010; 44(4): e87 doi: 10.1097/MCG.0b013e3181c0945a
88
Anil Arora, Praveen Sharma. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology 2012; 2(2): 145 doi: 10.1016/S0973-6883(12)60103-0
89
Kazuya Nagao, Akinori Tamura, Takeshi Morimoto, Kiyotaka Shimamura, Hiroshi Yukawa, Haruyasu Ito, Fujio Hayashi, Toshinori Makita, Genzou Takemura, Yukihito Sato, Tsukasa Inada, Takeshi Kimura, Masaru Tanaka. Liver fibrogenesis marker, 7S domain of collagen type IV in patients with acutely decompensated heart failure: Correlates, prognostic value and time course. International Journal of Cardiology 2017; 236: 483 doi: 10.1016/j.ijcard.2017.01.089
90
Fernanda BU Pulzi, Raul Cisternas, Murilo R Melo, Cristiane MF Ribeiro, Carlos A Malheiros, João E Salles. New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetology & Metabolic Syndrome 2011; 3(1) doi: 10.1186/1758-5996-3-3
91
Giada Sebastiani. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World Journal of Gastroenterology 2009; 15(18): 2190-2203 doi: 10.3748/wjg.15.2190
92
Steven J. Potts, Johanna K. DiStefano. Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Methods in Pharmacology and Toxicology 2014; : 101 doi: 10.1007/7653_2014_29
93
P. Halfon, M. Bourlière, G. Pénaranda, P. Cacoub. Les marqueurs sanguins non invasifs de fibrose hépatique au cours de l'infection chronique par le virus de l'hépatite C. La Revue de Médecine Interne 2006; 27(10): 751 doi: 10.1016/j.revmed.2006.03.037
94
Anna Mae Diehl, Steve S. Choi. Type 2 Diabetes Mellitus. Contemporary Endocrinology 2008; : 351 doi: 10.1007/978-1-60327-043-4_21
95
Ahmed M. Hashem, M. Emad M. Rasmy, Khaled M. Wahba, Olfat G. Shaker. Single stage and multistage classification models for the prediction of liver fibrosis degree in patients with chronic hepatitis C infection. Computer Methods and Programs in Biomedicine 2012; 105(3): 194 doi: 10.1016/j.cmpb.2011.10.005
96
Geum-Youn Gwak. Diagnosis of Non-alcoholic Fatty Liver Disease. The Journal of Korean Diabetes 2014; 15(2): 82 doi: 10.4093/jkd.2014.15.2.82
97
H. Hesham A-Kader. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World Journal of Pediatrics 2009; 5(4): 245 doi: 10.1007/s12519-009-0048-8
98
Takashi Kobayashi, Yuji Ogawa, Satoru Shinoda, Michihiro Iwaki, Asako Nogami, Yasushi Honda, Takaomi Kessoku, Kento Imajo, Masato Yoneda, Satoru Saito, Kouji Yamamoto, Satoshi Oeda, Hirokazu Takahashi, Yoshio Sumida, Atsushi Nakajima. A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-22767-z
99
Garfield A. Grandison, Paul Angulo. Can Nash Be Diagnosed, Graded, and Staged Noninvasively?. Clinics in Liver Disease 2012; 16(3): 567 doi: 10.1016/j.cld.2012.05.001
100
Akira Umemura, Akira Sasaki, Hiroyuki Nitta, Hirokatsu Katagiri, Shoji Kanno, Daiki Takeda, Taro Ando, Satoshi Amano, Masao Nishiya, Noriyuki Uesugi, Tamotsu Sugai. A novel second-stage surgical strategy for severely obese patient with pancreatic neuroendocrine tumor: a case report. Surgical Case Reports 2022; 8(1) doi: 10.1186/s40792-022-01484-9
101
Steven G Pearce, Nirav C Thosani, Jen-Jung Pan. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomarker Research 2013; 1(1) doi: 10.1186/2050-7771-1-7
102
Yohei Masugi, Tokiya Abe, Hanako Tsujikawa, Kathryn Effendi, Akinori Hashiguchi, Masanori Abe, Yasuharu Imai, Keisuke Hino, Shuhei Hige, Miwa Kawanaka, Gotaro Yamada, Masayoshi Kage, Masaaki Korenaga, Yoichi Hiasa, Masashi Mizokami, Michiie Sakamoto. Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. Hepatology Communications 2018; 2(1): 58 doi: 10.1002/hep4.1121
103
Yuichiro Eguchi, Gabriel Wong, Omar Akhtar, Yoshio Sumida. Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review. Hepatology Research 2020; 50(6): 645 doi: 10.1111/hepr.13502
104
Kadir Ozturk, Omer Kurt, Tolga Dogan, Alptug Ozen, Hakan Demirci, Fatih Yesildal, Murat Kantarcioglu, Turker Turker, Ahmet Kerem Guler, Yıldırım Karslioglu, Battal Altun, Ahmet Uygun, Sait Bagci. Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/1417962
105
Leon A. Adams, Paul Angulo. Role of Liver Biopsy and Serum Markers of Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease 2007; 11(1): 25 doi: 10.1016/j.cld.2007.02.004
106
Luca Miele, Alessandra Forgione, Giuseppe La Torre, Vittoria Vero, Consuelo Cefalo, Simona Racco, Valerio G. Vellone, Fabio M. Vecchio, Giovanni Gasbarrini, Gian Lodovico Rapaccini, Manuela G. Neuman, Antonio Grieco. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Translational Research 2009; 154(4): 194 doi: 10.1016/j.trsl.2009.06.007
107
Samer S. El‐Kamary, Mona M. Mohamed, Maissa El‐Raziky, Michelle D. Shardell, Olfat G. Shaker, Wafaa A. ElAkel, Gamal Esmat. Liver fibrosis staging through a stepwise analysis of non‐invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver International 2013; 33(7): 982 doi: 10.1111/liv.12139
108
Pauliina Tuomikoski, Kristiina Aittomäki, Tomi S. Mikkola, Anne Ropponen, Olavi Ylikorkala. Effect of oral and transdermal hormone therapy on hyaluronic acid in women with and without a history of intrahepatic cholestasis of pregnancy. American Journal of Obstetrics and Gynecology 2008; 198(4): 375.e1 doi: 10.1016/j.ajog.2007.10.804
109
Sahar Rostami, Hadi Parsian. Hyaluronic Acid: From Biochemical Characteristics to its Clinical Translation in Assessment of Liver Fibrosis. Hepatitis Monthly 2013; 13(12) doi: 10.5812/hepatmon.13787
110
Jun Chen, Jayant A. Talwalkar, Meng Yin, Kevin J. Glaser, Schuyler O. Sanderson, Richard L. Ehman. Early Detection of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease by Using MR Elastography. Radiology 2011; 259(3): 749 doi: 10.1148/radiol.11101942
111
C. Rinaldi A. LESMANA, Irsan HASAN, Unggul BUDIHUSODO, Rino A. GANI, Ening KRISNUHONI, Nurul AKBAR, Laurentius A. LESMANA. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non‐alcoholic steatohepatitis. Journal of Digestive Diseases 2009; 10(3): 201 doi: 10.1111/j.1751-2980.2009.00386.x
112
Giada Sebastiani, Konstantinos Gkouvatsos, Mario Plebani. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. cclm 2011; 49(1): 13 doi: 10.1515/CCLM.2011.001
113
Hilmar K Lückhoff, Frederik C Kruger, Maritha J Kotze. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World Journal of Hepatology 2015; 7(9): 1192-1208 doi: 10.4254/wjh.v7.i9.1192
114
M. Yoneda, M. Yoneda, H. Mawatari, K. Fujita, H. Endo, H. Iida, Y. Nozaki, K. Yonemitsu, T. Higurashi, H. Takahashi, N. Kobayashi, H. Kirikoshi, Y. Abe, M. Inamori, K. Kubota, S. Saito, M. Tamano, H. Hiraishi, S. Maeyama, N. Yamaguchi, S. Togo, A. Nakajima. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Digestive and Liver Disease 2008; 40(5): 371 doi: 10.1016/j.dld.2007.10.019
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345